We develop technologies that enable breakthroughs in Diagnostics, Antibody Platforms, Therapeutics and Vaccines.
The Burnet Vaccine Initiative (BVI) aims to develop a pipeline of novel vaccines across a variety of modalities (protein, DNA vector, mRNA) through four parallel development streams.
We are developing biologic and small molecule therapeutics that have potential application in women's health, infectious disease & immunological conditions.
The Burnet Diagnostics Initiative (BDI) is producing commercially viable products for unmet health needs.
We are developing platforms to enhance efficacy of antibodies, Fc-fusion proteins, and antibody-like biologics that have potential application in oncology, infectious disease and immunological conditions.
Commercialisation at Burnet
In collaboration with our laboratory, clinical and field researchers, we work to achieve real world impact by effectively translating scientific innovation into products or services. To achieve these impacts, our team of commercialisation specialists identify market opportunity, develop business plans, secure external funding, protect intellectual property, and establish industry partnerships.Find out more
The latest on how Burnet is closing the gap in health equity through a combination of collaborations and partnerships, established systems, resources and processes, and practical solutions for unmet health needs.
In collaboration with commercial partners we develop its intellectual property (IP) and over many years have developed a number of applications that are now in use around the world. Collaborate and partner with us in translating research into tangible commercial outcomes.Contact us